Barrow Hanley Mewhinney & Strauss LLC Has $371.24 Million Stock Position in Sanofi (NASDAQ:SNY)

Barrow Hanley Mewhinney & Strauss LLC lessened its holdings in Sanofi (NASDAQ:SNY - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,697,289 shares of the company's stock after selling 140,540 shares during the quarter. Sanofi accounts for approximately 1.3% of Barrow Hanley Mewhinney & Strauss LLC's investment portfolio, making the stock its 28th biggest position. Barrow Hanley Mewhinney & Strauss LLC owned about 0.30% of Sanofi worth $371,240,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Abel Hall LLC lifted its position in shares of Sanofi by 1.8% during the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after acquiring an additional 194 shares during the period. Providence Capital Advisors LLC lifted its position in Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after purchasing an additional 201 shares during the period. Keudell Morrison Wealth Management increased its holdings in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after buying an additional 217 shares during the period. Bailard Inc. raised its position in shares of Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after buying an additional 220 shares in the last quarter. Finally, Old Port Advisors lifted its holdings in shares of Sanofi by 0.6% during the 4th quarter. Old Port Advisors now owns 36,704 shares of the company's stock worth $1,770,000 after acquiring an additional 232 shares during the period. 14.04% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

SNY has been the subject of several research analyst reports. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $62.50.

Sanofi Price Performance

Shares of NASDAQ SNY traded down $1.12 during mid-day trading on Tuesday, hitting $54.34. 3,810,197 shares of the stock traded hands, compared to its average volume of 2,272,262. The company has a market cap of $137.91 billion, a PE ratio of 21.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a 50 day simple moving average of $55.22 and a two-hundred day simple moving average of $52.75.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.